A pioneering study has found that an individualized approach to breast cancer screening that assesses patients’ risk, rather than automatically giving annual mammograms, can lower the chance of more advanced cancers, while still safely matching people to the amount of screening they need.

In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made in a laboratory to stimulate the immune system to slow the progression of the disease by targeting amyloid plaques in the brain that are characteristic of Alzheimer’s.